ReviewDiabetic medicine : a journal of the British Diabetic Association2023
Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: A narrative review.
Review in Diabetic medicine : a journal of the British Diabetic Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study.Diabetes technology & therapeutics · 2025Trial
- Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial.BMJ open diabetes research & care · 2024Trial
- Efficacy of unblinded and blinded intermittently scanned continuous glucose monitoring for glycemic control in adults with type 1 diabetes.Frontiers in endocrinology · 2023Trial
- CGM Accuracy in a Fragmented Regulatory Landscape: A Commentary on Harmonisation and Recent Evidence.Diabetes, obesity & metabolism · 2026Article
- The Impact of Hypoglycaemia on Quality of Life in Adults With Type 1 Diabetes Using Contemporary Diabetes Technologies: A US National Survey.Diabetes, obesity & metabolism · 2026Article
- Treatment burden and health-related quality of life in young adults with type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- The Lived Experiences of Adult Continuous Glucose Monitor Users with Type 1 Diabetes with Recurrent Severe Hypoglycemic Events and Impaired Awareness of Hypoglycemia: A Qualitative Study.Advances in therapy · 2026Article
- A consensus statement on a National Competency Framework for training and assessment of knowledge and skills in diabetes technologies, including hybrid closed loop (HCL), insulin pump systems, and continuous glucose monitoring (CGM) devices.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Diabetes Technologies in Ultra-Endurance Type 1 Diabetes: Qualitative Study.Journal of medical Internet research · 2026Article
- Experiences of Adults With Type 1 Diabetes Using Digital Health Technology for Diabetes Self-Care: Qualitative Study.JMIR diabetes · 2026Article
- Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy.Nature medicine · 2026Article
- Comparison of AID users and non-users regarding glycemic control and diabetes distress: A mixed-methods study.PloS one · 2026Article
- Continuous glucose monitoring, diabetes distress, and well-being in adults with type 1 diabetes: findings from a National Survey in Lithuania.Frontiers in clinical diabetes and healthcare · 2026Article
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.Diabetes, obesity & metabolism · 2025Article
- Disconnect between advanced diabetes technology and psychological well-being among young people: a cross-sectional analysis.BMJ open diabetes research & care · 2025Article
- Continuous glucose monitoring remote monitoring does not meet the needs of all adult users: A qualitative study of adults with type 1 diabetes who do not use remote monitoring.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Potential benefits of hybrid closed-loop systems for managing moderate- to high-risk individuals with type 1 diabetes during Ramadan fasting.Diabetes, obesity & metabolism · 2025Article
- Practical Considerations and Implementation of Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2025Review
- Practical Considerations and Implementation of Automated Insulin Delivery Systems.Diabetes technology & therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo explore the association between the use of glycaemic technologies and person-reported outcomes (PROs) in adults with type 1 diabetes (T1D).
methodsWe included T1D and technology publications reporting on PROs since 2014. Only randomised controlled trials and cohort studies that used validated PRO measures (PROMs) were considered.
resultsT1D studies reported on a broad range of validated PROMs, mainly as secondary outcome measures. Most studies examined continuous glucose monitoring (CGM), intermittently scanned CGM (isCGM), and the role of continuous subcutaneous insulin infusion (CSII), including sensor-augmented CSII and closed loop systems. Generally, studies demonstrated a positive impact of technology on hypoglycaemia-specific and diabetes-specific PROs, including reduced fear of hypoglycaemia and diabetes distress, and greater satisfaction with diabetes treatment. In contrast, generic PROMs (including measures of health/functional status, emotional well-being, depressive symptoms, and sleep quality) were less likely to demonstrate improvements associated with the use of glycaemic technologies. Several studies showed contradictory findings, which may relate to study design, population and length of follow-up. Differences in PRO findings were apparent between randomised controlled trials and cohort studies, which may be due to different populations studied and/or disparity between trial and real-world conditions.
conclusionsPROs are usually assessed as secondary outcomes in glycaemic technology studies. Hypoglycaemia-specific and diabetes-specific, but not generic, PROs show the benefits of glycaemic technologies, and deserve a more central role in future studies as well as routine clinical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.